Malarsjukhuset Eskilstuna

The research at Malarsjukhuset Eskilstuna focuses on patients with atrial fibrillation and advanced chronic kidney disease stage 5. The primary aim is to evaluate the effectiveness and safety of apixaban for stroke prevention, seeking to lower the risk of ischemic events while maintaining an acceptable bleeding profile.

• Efficacy of anticoagulation in CKD stage 5
• Safety of anticoagulants in patients on dialysis
• Impact on incidence of ischemic stroke and systemic embolism

With 10 investigators and two active studies, the department advances cardiovascular care through rigorous evaluation of novel anticoagulant strategies.

In the oncology unit, the focus is on resectable colon cancer characterized by dMMR/MSI‑H. The trial investigates peri‑operative use of dostarlimab compared with standard treatment, aiming to improve surgical outcomes and long‑term disease control.

• Peri‑operative immunotherapy for resectable colon cancer
• Outcomes in dMMR/MSI‑H tumor subtypes
• Comparison with standard of care approaches

Conducted by a team of 10 investigators, this research contributes to advancing cancer therapeutics at Malarsjukhuset Eskilstuna.